Cardio-Oncology Market is projected to surpass USD 5.92 billion in 2031 at a CAGR of 6.8%

According to a research study published by Knowledge Sourcing Intelligence (KSI), the cardio-oncology market will expand from USD 4.27 billion in 2026 to USD 5.92 billion in 2031 at a CAGR of 6.8% during the forecast period.

The growing emphasis to reduce therapy induced cardio-toxicity, followed by a regulatory shift towards much more stringent safety evaluation protocols, is driving the overall market expansion.

Access sample report or view details: https://www.knowledge-sourcing.com/report/cardio-oncology-market/request

Key Market Insight & Emerging Trends:

The growing cancer prevalence has escalated the requirement for more advanced therapy and treatment options to improve cancer survivorship. However, such treatment options further pose other health challenges in the long term, especially cardiac-related, thereby driving the demand for specialized cardiac-care monitoring.

Complexities caused by cancer in overall health monitoring have escalated the need for multidisciplinary options that further improve treatment outcomes. Ongoing development in cardioprotective agents and antihypertensive drugs to minimize the late-onset cardiovascular complications is set to amplify the market demand for cardio-oncology drugs post-treatment. The regulatory shift and guidelines set by governing authorities like the FDA are further shaping the market trajectory.

Implementation of campaigns and events like “ESC Cardio-Oncology 2025” to spread awareness regarding cardiovascular side effects post cancer treatment is propelling the market growth. Furthermore, ongoing research on cardio-oncology drug development by major institutes like the University of Alberta, followed by the establishment of an AI-cardio-oncology initiative, will further the overall market development.

• Among global geographic regions, North America accounted for a major market share in 2025 owing to a mature healthcare infrastructure, which is exercising new treatment options for cancer patients.

• Based on therapy, cardioprotective agents accounted for a noteworthy share, fuelled by the growing efforts to reverse radiation-induced heart damage during chemotherapy.

• Based on drug class, beta-blockers held a major market share, fueled by the ongoing development of drugs preventing CTRCD (Cancer Therapy-Related Cardiac Dysfunction)

• By indication, chemotherapy-induced cardiotoxicity accounted for a significant market share, fueled by the progression in demand for early intervention therapies.

• Based on the route of administration, oral held a considerable share, fuelled by the growing emphasis on convenient cardiovascular management and medical supervision.

• Based on end user, hospitals dominate the market, as such healthcare establishments integrate all complex treatment capabilities for oncology and cardiology.

The competitive landscape in the cardio-oncology market is characterized by strategic investments and research collaborations undertaken by the key market players who seek to extend their cardiovascular and oncology-related product portfolios.

Therapy Type Insights: Cardioprotective Agents Hold a Considerable Share of the Market

Based on therapy type, cardioprotective agents constitute a considerable market share, primarily driven by the growing focus on the comprehensive treatment options that can manage vascular and thrombosis complications and comply with treatment protocols.

Drug Class Insights: Efforts to Address the CTRCD Complications

Beta-blockers and ACE inhibitors are the two leading drug classes in the market, driven by their ability to manage and monitor CTRCD (Cancer Therapy-Related Cardiac Dysfunction). Similarly, such drugs further prevent the LVEF decline in patients receiving HER-2 anthracycline therapies.

Indication Insights: Chemotherapy-Induced Cardiotoxicity Grows Due to High Drug Potency

By indication, chemotherapy-induced cardiotoxicity is expected to account for a major share of the market, fuelled by the growing progressive frequency of cancer survivorship, followed by the adoption of multi-drug regimens, which have further amplified heart damage in cancer patients.

Route of Administration Insights: Oral Drugs Show Significant Growth

By route of administration, the oral route is expected to show considerable growth and will account for a major share of the market, fuelled by the ongoing development of oral agents like ARBs and beta-blockers for hypertension and primary/secondary CTRCD management. Real-world studies also indicate pharmacist-led intervention involving oral cardioprotective.

End User Insights: Hospitals maintain dominance

End-user-wise, hospitals held a significant share of the market owing to the well-established infrastructure and care-delivery settings provided by such healthcare facilities for cancer patients. The establishment of cardio-oncology programs by healthcare centers in major global economies, followed by the introduction of multidisciplinary cardio-oncology services for cancer patients with cardiovascular history, has amplified the segment expansion.

Regional Highlights: North America Dominates while Asia Pacific Grows in Traction

North America remained a major regional market in 2025, driven by the ongoing expansion of cancer centers and investment in cardio-oncology-related drug research. Well-established presence of global players, namely Novartis AG, which has launched its “IHA” model to accelerate cancer detection and screening in the USA, has further expanded the market outlook for cardio-oncology. On the other hand, the Asia Pacific is projected to show significant growth owing to the healthcare expansion, development of advanced care models, followed by strategic manoeuvres and government initiatives undertaken to bolster oncology treatment.

Competitive Landscape

As a part of the report, the major players operating in the cardio-oncology market have been covered, such as Pfizer, Inc., Novartis AG, AstraZeneca, Roche Holding AG, Johnson & Johnson, Merck Co., Inc., and Sanofi. Such global players, through strategic collaboration and research investment in expanding their oncology and cardiovascular pipeline, are emphasizing addressing the growing treatment concern for cancer patients via their tailored products and therapies.

Market Segmentation

The report segments the cardio-oncology market as follows:

• By Therapy Type

  • Cardioprotective Agents

  • Anticoagulants

  • Antihypertensive Drugs

  • Antiarrhythmic Drugs

• By Drug Class

  • ACE-Inhibitors

  • Beta-Blockers

  • Antioxidants

  • Direct Oral Anticoagulants (DOACs)

• By Indication

  • Chemotherapy-Induced Cardiotoxicity

  • Radiation-Induced Cardiotoxicity

  • Cancer-Associated Thrombosis

  • Arrhythmias

• By Route of Administration

  • Oral

  • Injectable

• By End User

  • Hospitals

  • Oncology Clinics & Cardiology Centers

• By Geography

  • North America

    • USA

    • Canada

    • Mexico

  • South America

    • Brazil

    • Others

  • Europe

    • Germany

    • United Kingdom

    • France

    • Italy

    • Spain

    • Others

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • Others

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Others

Companies Profiled:

• Pfizer, Inc.

• Bristol-Myer Squibb

• Novartis-AG

• AstraZeneca

• Roche Holding AG

• Johnson & Johnson

• Bayer AG

• Merck & Co., Inc

• Sanofi

• Amgen Inc.

Explore More Reports:

• Global Cardiovascular Anticoagulants Market

• AI in Cardiovascular Diagnostics Market

• Echocardiography Market